title: Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas.
abstract: Pegylated liposomal doxorubicin (Peg-Doxo) is a promising drug for advanced/recalcitrant primary cutaneous T-cell lymphomas (CTCLs). This prospective phase II trial enrolled 19 patients. We observed overall and complete response rates of 84.2% and 42.1% (with no significant differences between stage I-IIA and IIB-IV patients), and 11% grade III/IV toxicity. After a maximum 46 month-follow-up, median overall (OS), event-free (EFS) and progression-free (PFS) survival were 34, 18 and 19 months. OS, EFS and PFS rates at 46 months were 44%, 30% and 37% respectively. Peg-Doxo seems to be an active and safe principle that should be used in plurirelapsed, early stage-MF and in combination with other chemotherapeutic agents in advanced and aggressive CTCLs.
authors.affiliation: Clinic of Hematology, Polytechnic University of the Marche, Medical School, Ospedali Riuniti Umberto I, G.M. Lancisi-G. Salesi, Ancona, Italy. stpulini@bigfoot.com
authors.forename: Stefano
authors.initials: S
authors.lastname: Pulini
authors.forename: Serena
authors.initials: S
authors.lastname: Rupoli
authors.forename: Gaia
authors.initials: G
authors.lastname: Goteri
authors.forename: Nicola
authors.initials: N
authors.lastname: Pimpinelli
authors.forename: Renato
authors.initials: R
authors.lastname: Alterini
authors.forename: Angela
authors.initials: A
authors.lastname: Tassetti
authors.forename: Anna Rita
authors.initials: AR
authors.lastname: Scortechini
authors.forename: Massimo
authors.initials: M
authors.lastname: Offidani
authors.forename: Simonetta
authors.initials: S
authors.lastname: Mulattieri
authors.forename: Andrea
authors.initials: A
authors.lastname: Stronati
authors.forename: Giuliano
authors.initials: G
authors.lastname: Brandozzi
authors.forename: Alfredo
authors.initials: A
authors.lastname: Giacchetti
authors.forename: Giorgio
authors.initials: G
authors.lastname: Mozzicafreddo
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Ricotti
authors.forename: Giorgio
authors.initials: G
authors.lastname: Filosa
authors.forename: Alberta
authors.initials: A
authors.lastname: Bettacchi
authors.forename: Marco
authors.initials: M
authors.lastname: Simonacci
authors.forename: Nicolino
authors.initials: N
authors.lastname: Novelli
authors.forename: Pietro
authors.initials: P
authors.lastname: Leoni
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008081:Liposomes / Q000008:administration & dosage; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000188:drug therapy; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D012074:Remission Induction; D016879:Salvage Therapy; D012751:Sezary Syndrome / Q000188:drug therapy; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D008081:Liposomes; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin